Publication of Circular & Notice of GM
Verici Dx Plc has published a Circular and issued a Notice of General Meeting to be held on June 22, 2026, to grant the Company authority to issue new Ordinary Shares on a non-pre-emptive basis following a fundraising announced on June 5, 2026. This action is crucial for the company's ability to raise capital and potentially fund its operations and growth initiatives in the organ transplant diagnostics sector.
Select text to share a quote on X · sign in to keep highlights & notes in your VRCI notes
Verici Dx Plc, (AIM: VRCI), a developer of advanced clinical diagnostics for organ transplant, announces that a Circular has been published containing a notice of a general meeting to be held at the offices of Shoosmiths LLP at 1 Bow Churchyard, London, EC4M 9DQ at 11:30 a.m. on 22 June 2026 ("General Meeting").
The General Meeting is being held to ensure that the Company has sufficient authority to issue and allot new Ordinary Shares on a non-pre-emptive basis following the Fundraising announced on 5 June 2026.
The Circular and Notice of General Meeting has been posted to Shareholders and is available on the Company's website at:
Enquires:
| Verici Dx plc | www.vericidx.com |
| Sara Barrington, CEO Julian Baines, Chairman | Via Walbrook PR |
| Singer Capital Markets (Nominated Adviser, Joint Broker & Joint Bookrunner) | Tel: +44 (0)20 7496 3000 |
| Phil Davies / Jalini Kalaravy / Anastassiya Eley | |
| Oberon Capital (Joint Broker & Joint Bookrunner) | Tel: +44 (0)20 3179 0500 |
| Mike Seabrook / Adam Pollock / Heena Karani | |
| Walbrook PR (Media & Investor Relations) | Tel: +44 (0)20 7933 8780 or vericidx@walbrookpr.com |
| Alice Woodings / Rachel Broad | Mob: +44 (0)7407 804 654 / +44 (0)7747 515 393 |
Verici Dx
Cleaned text: letterheads, contacts and legal notices removed. View the original announcement ↗ · Company filings. Not investment advice.